134 related articles for article (PubMed ID: 8931119)
1. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
Melarange R; Spangler R; Hoult JR
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
[TBL] [Abstract][Full Text] [Related]
2. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
3. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
[TBL] [Abstract][Full Text] [Related]
5. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
[TBL] [Abstract][Full Text] [Related]
6. The unique pharmacologic profile of nabumetone.
Blower PR
J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.
Ishiwata Y; Okamoto M; Yokochi S; Hashimoto H; Nakamura T; Miyachi A; Naito Y; Yoshikawa T
J Pharm Pharmacol; 2003 Feb; 55(2):229-37. PubMed ID: 12635655
[TBL] [Abstract][Full Text] [Related]
8. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA.
Pillinger MH; Dinsell V; Apsel B; Tolani SN; Marjanovic N; Chan ES; Gomez P; Clancy R; Chang LF; Abramson SB
Br J Pharmacol; 2004 Jul; 142(6):973-82. PubMed ID: 15210577
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
10. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
[TBL] [Abstract][Full Text] [Related]
11. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
Soma LR; Uboh CE; Rudy JA; Smith MS
Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Melarange R; Rashbrook LC
J Pharm Pharmacol; 1987 Sep; 39(9):717-20. PubMed ID: 2445949
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Melarange R; Gentry C; Durie M; O'Connell C; Blower PR
Dig Dis Sci; 1994 Mar; 39(3):601-8. PubMed ID: 8131699
[TBL] [Abstract][Full Text] [Related]
14. Effects of the prodrug nabumetone, and its active metabolite, 6-MNA, on human and rat gastric mucosal prostanoids and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Drugs; 1990; 40 Suppl 5():53-6. PubMed ID: 2081494
[No Abstract] [Full Text] [Related]
15. The science--equivalent efficacy and diminished risk.
Blower P
Eur J Rheumatol Inflamm; 1991; 11(3):29-37. PubMed ID: 1365477
[TBL] [Abstract][Full Text] [Related]
16. Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
[TBL] [Abstract][Full Text] [Related]
17. Different effects of indomethacin and nabumetone on prostaglandin-mediated gastric responses to central vagal activation in rats.
Cardin S; Soll AH; Taché Y
J Pharmacol Exp Ther; 1995 Nov; 275(2):667-73. PubMed ID: 7473153
[TBL] [Abstract][Full Text] [Related]
18. Effect of 6-Methoxy-2-Naphthylacetic Acid (6MNA), the Active Metabolite of Nabumetone, on the Glycosaminoglycan Synthesis of Canine Articular Cartilage In Vitro : Comparison with Other Nonsteroidal Anti-Inflammatory Drugs.
Gentry C; Blower P; Spangler R
Clin Drug Investig; 1995 Dec; 10(6):355-64. PubMed ID: 27519337
[TBL] [Abstract][Full Text] [Related]
19. An overview of the clinical pharmacokinetics of nabumetone.
Hyneck ML
J Rheumatol Suppl; 1992 Nov; 36():20-4. PubMed ID: 1474531
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.
Matsumoto K; Nemoto E; Hasegawa T; Akimoto M; Sugibayashi K
Biol Pharm Bull; 2011; 34(5):734-9. PubMed ID: 21532165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
